RAPT Therapeutics, Inc. (RAPT) Income from Continuing Operations (2020 - 2024)
RAPT Therapeutics' Income from Continuing Operations history spans 5 years, with the latest figure at 54465000.0 for Q4 2024.
- For Q4 2024, Income from Continuing Operations fell 63.97% year-over-year to 54465000.0; the TTM value through Dec 2024 reached 136101000.0, down 7.11%, while the annual FY2024 figure was 136101000.0, 7.11% down from the prior year.
- Income from Continuing Operations for Q4 2024 was 54465000.0 at RAPT Therapeutics, down from 19788000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 10794000.0 in Q4 2020 and bottomed at 54465000.0 in Q4 2024.
- The 5-year median for Income from Continuing Operations is 20282500.0 (2022), against an average of 23318650.0.
- The largest YoY upside for Income from Continuing Operations was 41.66% in 2024 against a maximum downside of 63.97% in 2024.
- A 5-year view of Income from Continuing Operations shows it stood at 10794000.0 in 2020, then tumbled by 40.72% to 15189000.0 in 2021, then plummeted by 60.85% to 24431000.0 in 2022, then crashed by 35.96% to 33217000.0 in 2023, then crashed by 63.97% to 54465000.0 in 2024.
- Per Business Quant, the three most recent readings for RAPT's Income from Continuing Operations are 54465000.0 (Q4 2024), 19788000.0 (Q3 2024), and 29330000.0 (Q2 2024).